Cellebrite DI Ltd. SEC filings document its foreign private issuer reporting for an AI-powered digital investigative and intelligence software business. Form 6-K current reports furnish quarterly and annual results releases, GAAP financial tables incorporated by reference into Form S-8 and Form F-3 registration statements, and annual general meeting voting results under the Israeli Companies Law and the company’s articles of association.
The filing record also includes Form 20-F annual reporting, which provides the recurring public-company framework for Cellebrite’s business, financial reporting and ordinary-share governance disclosures.
David Gee, a shareholder of Cellebrite DI Ltd., filed a notice of proposed sale under Rule 144 to sell 1,165 ordinary shares (par value NIS 0.00001), with an aggregate market value of $16,612.90, through Morgan Stanley Smith Barney on or about February 12, 2026.
The filing notes that these securities relate to restricted share units that vested on February 12, 2026 under an issuer S-8 registered plan, with 2,618 shares acquired as employee compensation. The notice also reports prior sales in the last three months totaling 3,704 shares for $63,121.53 and 1,969 shares for $33,236.72, and states that 248,830,759 ordinary shares were outstanding. Gee represents that he is not aware of undisclosed material adverse information about Cellebrite.
Cellebrite DI Ltd. insider plans a small stock sale under Rule 144. Marcus Jewell filed to sell 1,779 ordinary shares, par value NIS 0.00001, through Morgan Stanley Smith Barney LLC on or about 02/12/2026 on Nasdaq, with an aggregate market value of $25,368.54. The filing notes 248,830,759 ordinary shares outstanding.
The shares to be sold come from 4,187 restricted share units that vested under an issuer S‑8 registered employee compensation plan. Over the prior three months, Jewell sold 12,543 and 9,592 ordinary shares on 11/17/2025 and 11/18/2025, generating gross proceeds of $230,372.06 and $174,286.64.
Cellebrite DI Ltd. reported record fourth-quarter and full-year 2025 results, highlighted by strong growth in recurring software revenue and profitability. Total annual recurring revenue (ARR) rose 21% to $480.8 million, reflecting expansion across major geographies and the contribution from the Corellium acquisition.
Full-year 2025 revenue increased to $475.7 million from $401.2 million, while net income improved to $78.3 million compared with a loss of $283.0 million in 2024. Adjusted EBITDA reached $127.6 million for the year, a 26.8% margin, and free cash flow was $160.3 million, a 33.7% margin.
For 2026, Cellebrite targets ARR of $567–$573 million and revenue of $565–$571 million, implying high-teens growth, with adjusted EBITDA of $149–$155 million and a 26–27% margin, signaling expectations of continued scalable, profitable expansion.
Cellebrite DI Ltd. submitted a Form 6-K to furnish a press release titled “Cellebrite Announces Third-Quarter 2025 Results.” The filing states that the press release, dated November 12, 2025, contains the company’s third-quarter 2025 results and GAAP financial statement tables.
The filing also explains that these GAAP financial statement tables are incorporated by reference into Cellebrite’s existing registration statements on Form S-8 and Form F-3 with the U.S. Securities and Exchange Commission. The report is signed on behalf of the company by its Chief Financial Officer, David Barter.
Form 144 notice shows a proposed sale of 25,390 common shares of Cellebrite DI Ltd. (CLBT) through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $478,949.34. The filing reports 244,469,106 shares outstanding, so the proposed sale equals roughly 0.01% of the outstanding stock.
The securities listed were mainly acquired under the issuer’s registered plans: two lots of 4,829 shares each from option exercises on 10/06/2025 and 15,732 shares from restricted stock vesting on 02/14/2024. The filer also disclosed two recent sales by the same person in September 2025 totaling 40,044 shares for gross proceeds of $707,057.23. The signer certifies no undisclosed material adverse information.
Cellebrite DI Ltd. (CLBT) Form 144 shows a proposed sale of 508,790 common shares, with an aggregate market value of $9,366,104.61, to be sold on or about 09/24/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The filing breaks out how the shares were acquired: 10,373 shares from restricted stock dated 09/17/2025 and 498,417 shares from a stock option exercise on 09/24/2025 paid in cash. It also discloses a recent sale of 6,847 shares on 09/02/2025 for gross proceeds of $112,016.92. The filer attests there is no undisclosed material adverse information.
Form 144 filing for Cellebrite DI Ltd. (CLBT) reports a proposed sale of 40,535 common shares held as restricted stock units acquired on 02/15/2023. The filing lists Morgan Stanley Smith Barney LLC as the broker and an approximate aggregate market value of $728,413.95 with an expected sale date of 09/23/2025 on NASDAQ. The filer represents they are unaware of any undisclosed material adverse information. The filing also discloses 10b5-1 sales executed on 09/22/2025 totaling 25,810 shares for gross proceeds of $464,610.97. The issuer’s total shares outstanding are stated as 244,469,106.
Form 144 filing for Cellebrite DI Ltd. (CLBT) reports a proposed sale of 40,535 common shares held as restricted stock units acquired on 02/15/2023. The filing lists Morgan Stanley Smith Barney LLC as the broker and an approximate aggregate market value of $728,413.95 with an expected sale date of 09/23/2025 on NASDAQ. The filer represents they are unaware of any undisclosed material adverse information. The filing also discloses 10b5-1 sales executed on 09/22/2025 totaling 25,810 shares for gross proceeds of $464,610.97. The issuer’s total shares outstanding are stated as 244,469,106.
Cellebrite DI Ltd. (CLBT) filed a Form 144 reporting a proposed sale of 34,151 ordinary shares on 09/22/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $601,399.11 and 245,691,023 shares outstanding. The shares were acquired as 107,008 Restricted Stock Units on 09/19/2025 from Cellebrite DI Ltd. and were received as compensation. The filing indicates no reported sales by the seller in the past three months. Several filer identification fields in the public extract (CIK/CCC and contact details) are blank in the provided text.
Cellebrite DI Ltd. (CLBT) filed a Form 144 reporting a proposed sale of 34,151 ordinary shares on 09/22/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $601,399.11 and 245,691,023 shares outstanding. The shares were acquired as 107,008 Restricted Stock Units on 09/19/2025 from Cellebrite DI Ltd. and were received as compensation. The filing indicates no reported sales by the seller in the past three months. Several filer identification fields in the public extract (CIK/CCC and contact details) are blank in the provided text.
Form 144 notice for proposed sale of securities by an insider or affiliate. The filing reports an intended sale of 25,810 shares of Common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $454,514.10. The shares are listed on NASDAQ and the approximate sale date provided is 09/22/2025. The shares were acquired as restricted stock units from the issuer on 02/15/2023, and no related securities sales were reported in the prior three months. Several filer and issuer identification fields are left blank in the supplied content.
Form 144 notice for proposed sale of securities by an insider or affiliate. The filing reports an intended sale of 25,810 shares of Common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $454,514.10. The shares are listed on NASDAQ and the approximate sale date provided is 09/22/2025. The shares were acquired as restricted stock units from the issuer on 02/15/2023, and no related securities sales were reported in the prior three months. Several filer and issuer identification fields are left blank in the supplied content.
Cellebrate DI Ltd. reports that shareholders approved all proposals presented at its annual general meeting of shareholders held on September 19, 2025. These proposals were adopted by the requisite majority in accordance with Israeli law and the company’s articles, as outlined in the proxy statement previously provided to investors.
The meeting had strong participation, with 188,039,771 ordinary shares represented, equal to approximately 76.82% of issued and outstanding ordinary shares as of the record date. This report is also incorporated by reference into Cellebrite’s existing registration statements on Form S-8 and Form F-3.
Cellebrate DI Ltd. reports that shareholders approved all proposals presented at its annual general meeting of shareholders held on September 19, 2025. These proposals were adopted by the requisite majority in accordance with Israeli law and the company’s articles, as outlined in the proxy statement previously provided to investors.
The meeting had strong participation, with 188,039,771 ordinary shares represented, equal to approximately 76.82% of issued and outstanding ordinary shares as of the record date. This report is also incorporated by reference into Cellebrite’s existing registration statements on Form S-8 and Form F-3.